MilliporeSigma | December 30, 2021
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has been awarded a $136.7M USD contract award for the construction of a lateral flow membrane production facility over a three-year period at the company's Sheboygan, Wisconsin site. The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness.
"With this agreement, MilliporeSigma will construct a state-of-the-art lateral flow membrane production facility that will give our in vitro diagnostic (IVD) manufacturing customers greater flexibility and security of supply of our Hi-Flow™ Plus lateral flow membranes."
Matthias Heinzel, Member of the Executive Board and CEO, Life Science, Merck KGaA, Darmstadt, Germany
"Our lateral flow membranes have earned a reputation for high consistency among rapid diagnostic manufacturers and the already robust demand for this membrane has significantly increased since the onset of the pandemic. With this critical investment, we are expanding much-needed access to essential diagnostic testing as a trusted partner to the world's most sophisticated diagnostic manufacturers," said Jean-Charles Wirth, head of Applied Solutions, Life Science.
Building this new facility supports the overall Life Science business sector's strategy to add physical capacity and expand its regional network to enable further growth of its key portfolios.
Hi-Flow™ Plus Lateral flow membrane is used in rapid diagnostic test kit manufacturing by the Life Science business' customers, enabling reproducible results due to its consistent quality and optimized properties. The rapid test kits are used for a variety of applications, including Infectious Disease testing (Covid-19, HIV, Influenza, Malaria, etc.), as well as in women's health, biomarker detection, drug testing, food safety and animal health. Due to continuously increasing demand for lateral flow membrane, the Life Science business had already invested in a second membrane casting line in Cork, Ireland, which was recently completed, and expanded the range of other critical reagents (antibodies, beads, blockers, buffers) utilized to develop lateral flow rapid test kits. These strategic investments position the Life Science business as an important critical raw material supplier for the Diagnostic market, especially as the company prepares for IVD Regulation and Medical Device Regulation.
The Life Science business is undertaking an ambitious, multi-year program to increase production capacity and capabilities to support the growing global demand for lifesaving vaccines, therapies and diagnostics. Within the last year, the company has accelerated investments to expand capacity to produce its support Mobius® single-use assemblies in both the U.S. and France, as well as increased capacity for the production of cell culture media in the U.S. and UK, among others. Additionally, several expansion projects continue to advance across the company's manufacturing and distribution global network.
About the Life Science business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 23,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.
Noblis | September 27, 2021
Noblis, Inc., a leading provider of science, technology and strategy services to the federal government, today announced the launch of its RunGrants™ solution to automate, streamline and expedite the grants management process from end-to-end. A Cloud-based grants solution, it centralizes relevant data to improve decision making and can be configured to meet unique agency and mission needs. RunGrants is the third offering announced within Noblis' Run solutions suite which helps government agencies and clients employ automation and analytics to streamline complex workflows, expedite and improve decision making and achieve broader IT modernization goals.
"Funding from federal grants programs powers a wide range of critical public and private initiatives. Prioritizing and funding these initiatives to ensure that the most critical needs are met at the right time and in the best interest of the public can be challenging. RunGrants was developed with this in mind. It provides a clear, modern and user-friendly method for submitting and tracking grant applications to help stakeholders on both sides of the process from application submission, to evaluation, to selection."
Mile Corrigan, senior vice president, Noblis' Federal Civil Solutions
For more than a decade, Noblis has been helping to automate the federal grants lifecycle. With RunGrants, this expertise translates to a cloud-based solution that is:
Automated – Delivers speed and accuracy improvements while reducing the need for management intervention in a highly secure platform.
Standards-Based – Consolidates data for greater interoperability and support for modernization goals.
Flexible – A low-code framework to easily customize for workflows, reports and functionality to match each agency's unique environment.
Data-Driven – Gives managers and agency leadership deep insight into every aspect of the grants process for better awareness and decision making.
Cost-Effective – Software-as-a-Service model means predictable costs, regular maintenance and improvements that keep up with evolving demands and a streamlined acquisition process.
About the Run with Noblis Solutions Suite
The Run with Noblis solutions suite addresses the evolving needs of federal agencies with the speed, performance and scale of digital solutions that create insights, automate workflows, streamline processes and drive greater outcomes. Learn more at noblis.org/run.
Noblis is a dynamic science, technology and strategy organization dedicated to creating forward-thinking technical and advisory solutions in the public interest. We bring the best of scientific thought, management and engineering expertise together in an environment of independence and objectivity to deliver enduring impact on federal missions. Noblis works with a wide range of government clients in the defense, homeland security, intelligence, law enforcement and federal civil sectors. Together with our subsidiaries, we tackle the nation's toughest problems and apply advanced solutions to our clients' most critical missions.
White House | August 07, 2020
President Donald Trump signed an executive order on Thursday banning transactions with ByteDance, the parent company of popular app TikTok . The White House also announced that he signed a similar order banning transactions with WeChat, a messaging app that is ubiquitous in China, but has a much smaller presence than TikTok in the United States, where it is used mainly by members of the Chinese diaspora, and its owner Tencent Holdings. Both orders will take effect in 45 days, but (and this is a key point) the executive orders are vague and confusing because they say Secretary of State Wilbur Ross will not identify what transactions are covered until then. It’s also still uncertain how the executive orders will affect the apps’ operations in the U.S.